Pancreatic cancer
Conditions
Interventions
H101 intratumoral injection combined with AG chemotherapy group:H101
H101 intratumoral injection combined with AG chemotherapy group:GEM + Nab-P
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Pancreatic cancer was diagnosed by preoperative imaging and laboratory examination, and was considered as unresectable by imaging evaluation, and the final pathological diagnosis confirmed; 2. The tumor was unresectable and no distant metastasis was found during intraoperative exploration, and the final pathological diagnosis confirmed; 3. Aged 18-75 years; 4. KPS score >= 60 points 5. Life expectancy of more than 2 months; 6. Patients or their legal representatives were willing to sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with non-ductal adenocarcinoma confirmed by biopsy; 2. Patients with severe pancreatic portal hypertension and subsequent injection therapy may be at higher risk of bleeding; 3. Severe, uncontrolled medical disorders that may impair the ability of the subjects to receive the prescribed treatment, including but not limited to HIV positive, active tuberculosis, HBV DNA copy number > 10^3 ml (no more than 10^4 ml); 4. The patient had a history of other malignancies (skin basal-cell carcinoma, excluding cervical carcinoma in situ) within 5 years; 5. Other chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy, or traditional Chinese medicine must be used concurrently during the trial for anti-tumor treatment; 6. The patient has used or is using chemotherapy or other antineoplastic drugs in the past; 7. Preoperative ultrasound evaluation showed that the tumor size was small, the tumor location was close to or behind the important blood vessels, and so on, which may lead to the low success rate of intratumoral injection of virus under ultrasound and the high incidence of complications after injection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| disease free survival;overall survival;surgical conversion rate;pain relief; | — |
Countries
China
Contacts
Public ContactChunlu Tan
Department of Pancreatic Surgery, West China Hospital, Sichuan University
Outcome results
None listed